LTZ Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2022-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)A Phase 1 Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Non-Hodgkin Lymphoma Refractory/ RelapsedDLBCL - Diffuse Large B Cell LymphomaMantle Cell Lymphoma (MCL)Follicular Lymphoma ( FL)Marginal Zone Lymphoma (MZL)
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- LTZ Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT07121946
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
News
No news found